Synairgen PLC (AIM:SNG, OTC:SYGGF) (AIM:SNG, OTC:SYGGF) CEO Richard Marsden joins Proactive London's Katie Pilbeam after the news that their antiviral treatment for severe lung infections will advance to the final stage of trials as part of a US government-sponsored programme.
The external data safety monitoring board of the ACTIV-2 study recommended Synairgen’s SNG001 go to Phase III trials in mild to moderate COVID-19 patients. SNG001 is a formulation for inhalation containing the broad-spectrum anti-viral protein interferon beta, a naturally occurring protein that orchestrates the body's antiviral responses.
As well as the ACTIV-2 trial, Marsden updates on their own Phase III trial, called SPRINTER, which is assessing SNG001 in hospitalised COVID-19 patients and expects to publish top-line results in early 2022.